大B细胞淋巴瘤CAR-T细胞疗效预测与风险分层研究进展OA
Research progress on efficacy prediction and risk stratification of CAR-T cell therapy in large B-cell lymphoma
嵌合抗原受体T(chimeric antigen receptor T,CAR-T)细胞疗法显著改善了复发或难治性大B细胞淋巴瘤(relapsed/refractory large B-cell lymphoma,R/R LBCL)患者的预后,但疗效个体差异显著,治疗全过程疗效预测与风险分层仍是难点.本文以治疗时间轴为主线,将疗效相关指标分为治疗前风险分层、输注后早期反应评估、动态复发监测和治疗失败后预后评估4类,明确各时间点检测内容、目的及对后续决策的影响;综述基线及早期正电子发射断层显像(positron emission tomography,PET)代谢参数、循环肿瘤DNA(circulating tumor DNA,ctDNA)清除动力学、细胞产品特征、肿瘤基因组学与免疫微环境、患者因素等研究进展.但鉴于多数指标缺乏统一阈值与前瞻性研究验证,未来应规范检测方法,开展前瞻性多中心研究,并关注人工智能与基础模型、可测量残留病灶指导策略、建立新型细胞治疗平台等方向,推动分层指导下的个体化治疗.
Chimeric antigen receptor(CAR)-T cell therapy has substantially improved outcomes in patients with relapsed/refractory large B-cell lymphoma(R/R LBCL);however,interindividual variability in efficacy remains considerable,and the efficacy prediction and risk stratification across the entire treatment course remain major challenges.Following the treatment timeline,this review categorizes efficacy-related indicators into four groups according to their roles at different stages of treatment:pre-treatment risk stratification,early post-infusion response assessment,dynamic relapse monitoring,and prognostic evaluation after treatment failure.It further clarifies what should be measured at each timepoint,why it should be measured,and how the results inform subsequent decisions.We review advances regarding baseline and early positron emission tomography(PET)metabolic parameters,circulating tumor DNA(ctDNA)clearance kinetics,CAR-T cell product characteristics,tumor genomics and the immune microenvironment,and host factors.Most indicators lack unified cut-offs and prospective validation.Future efforts should focus on standardizing detection methods,conducting prospective multicenter studies,and exploring directions such as artificial intelligence and foundation models,measurable residual disease(MRD)-guided strategies,dual-targeted CAR-T,CAR-NK,and in vivo CAR-T,so as to promote stratified,individualized therapy.
王博宇;王亮
100069 北京 首都医科大学100730 北京 首都医科大学附属北京同仁医院血液科
医药卫生
大B细胞淋巴瘤嵌合抗原受体T疗效预测风险分层分子影像循环肿瘤DNA
Large B-cell lymphomaChimeric antigen receptor TEfficacy predictionRisk stratificationMolecular imagingCircu-lating tumor DNA
《中国癌症防治杂志》 2026 (4)
464-478,15
癌症、心脑血管、呼吸和代谢性疾病防治研究国家科技重大专项(2025ZD0544300)
评论